Literature DB >> 11936525

Increased soluble CD14 in bronchoalveolar lavage fluid of stable lung transplant recipients.

C Ward1, E H Walters, L Zheng, H Whitford, T J Williams, G I Snell.   

Abstract

Macrophages, neutrophils and infection have been implicated in the genesis of the bronchiolitis obliterans syndrome (BOS) post lung transplantation. sCD14 is a soluble form of a shed-cell surface protein. It is capable of promoting cytokine-induced inflammation and it's presence in clinically stable lung transplant recipients (LTR) might be important as an early marker of BOS. Bronchalveolar lavage (BAL) and blood samples were taken from 26 stable LTR, at or near their best forced expiratory volume in one second who were free from infection. sCD14 levels were measured via enzyme-linked immunosorbent assay. Cell counts were performed on unfiltered BAL. LTR neutrophil count, BAL sCD14 and serum sCD14 levels were higher than controls (median 3.8% versus 1.3%, p<0.05; 11.5 ng x mL(-1) versus 6 ng x mL(-1), p<0.001; 6.2 microg x mL(-1) versus 2.4 microg x mL(-1), p<0.05, respectively). BAL albumin and sCD14 correlated (regression coefficient: 0.77, p<0.001). In this hypothesis-generating, cross-sectional study, the authors have described for the first time soluble CD14 levels in the bronchoalveolar lavage and serum of stable lung transplant recipients, and show that these are elevated compared to controls. This is a practicable candidate marker system, which can be tested for a predictive role in bronchiolitis obliterans syndrome following lung transplantation. The origin of this cellular protein and its temporal relationship to the development of the bronchiolitis obliterans syndrome remains to be elucidated in more definitive longitudinal studies, which should include other measurements potentially relevant to the innate immune system, such as bronchoalveolar lavage endotoxin levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936525     DOI: 10.1183/09031936.02.00225502

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients.

Authors:  C Ward; I A Forrest; D M Murphy; G E Johnson; H Robertson; T E Cawston; A J Fisher; J H Dark; J L Lordan; J A Kirby; P A Corris
Journal:  Thorax       Date:  2005-06-21       Impact factor: 9.139

2.  Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts.

Authors:  C Ward; I A Forrest; I A Brownlee; G E Johnson; D M Murphy; J P Pearson; J H Dark; P A Corris
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

Review 3.  Foregut Dysmotility in the Lung Transplant Patient.

Authors:  Danny Wong; Walter W Chan
Journal:  Curr Gastroenterol Rep       Date:  2021-10-15

Review 4.  Soluble CD14: role in atopic disease and recurrent infections, including otitis media.

Authors:  Karin C Lødrup Carlsen; Berit Granum
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

5.  Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases.

Authors:  Veronica Marcos; Phillip Latzin; Andreas Hector; Sebastian Sonanini; Florian Hoffmann; Martin Lacher; Barbara Koller; Philip Bufler; Thomas Nicolai; Dominik Hartl; Matthias Griese
Journal:  Respir Res       Date:  2010-03-19

6.  Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients.

Authors:  C Ward; M Cámara; I Forrest; R Rutherford; G Pritchard; M Daykin; A Hardman; A de Soyza; A J Fisher; P Williams; P A Corris
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 7.  Role of gastroesophageal reflux disease in lung transplantation.

Authors:  Kelly E Hathorn; Walter W Chan; Wai-Kit Lo
Journal:  World J Transplant       Date:  2017-04-24

8.  Soluble biomarkers associated with chronic lung disease in older children and adolescents with perinatal HIV infection.

Authors:  Dan Hameiri-Bowen; Evgeniya Sovershaeva; Trond Flaegstad; Tore Jarl Gutteberg; Lucky Gift Ngwira; Victoria Simms; Andrea M Rehman; Grace Mchugh; Tsitsi Bandason; Rashida Abbas Ferrand; Sarah Rowland-Jones; Louis-Marie Yindom
Journal:  AIDS       Date:  2021-09-01       Impact factor: 4.632

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.